



## IMMEDIATE ATTENTION REQUIRED DISPENSING ERROR ALERT

Dear Healthcare Professional,

Medication dispensing errors are a serious threat to quality healthcare and necessitate the combined efforts of all involved to minimize their occurrence. UCB Pharma, Inc. would like to advise you that dispensing errors may occur between **KEPPRA**<sup>®</sup> (levetiracetam) tablets and oral solution and **KALETRA**<sup>®</sup> (lopinavir/ritonavir) capsules and oral solution. Your assistance is requested in clearly communicating oral and written prescriptions for these two products to help avoid dispensing errors.

Patients erroneously receiving either medication would be unnecessarily subjected to the risk of adverse effects. In addition, patients with epilepsy who do not receive their antiepileptic drug due to a dispensing error would be inadequately treated and could experience serious consequences, including status epilepticus.

**KEPPRA**<sup>®</sup>, an <u>antiepileptic</u>, is available as tablets and oral solution. **KEPPRA**<sup>®</sup> tablets, 250 mg are blue, 500 mg are yellow, and 750 mg are orange, oblong-shaped, scored, film-coated tablets debossed with "ucb" and "strength" on one side. They are supplied in containers of 120 tablets. **KEPPRA**<sup>®</sup> oral solution is a clear, colorless, grape-flavored liquid supplied in 16 fl oz white HDPE bottles containing 500 mg levetiracetam per 5 mL.

**KALETRA**<sup>®</sup>, an <u>antiretroviral</u>, is available as capsules or oral solution. **KALETRA**<sup>®</sup> 133.3 mg lopinavir/33.3 mg ritonavir capsules are orange soft gelatin capsules imprinted with the Abbott corporate logo and "PK". **KALETRA**<sup>®</sup> is available in bottles of 180 capsules. **KALETRA**<sup>®</sup> oral solution is a light yellow to orange colored liquid supplied in amber-colored 160 mL glass bottles containing 400 mg lopinavir/100 mg ritonavir per 5 mL.

Please take great care when writing a prescription for **KEPPRA**® by making sure that **KEPPRA**® can be easily read and understood by the person filling the prescription. Clearly communicating both written and verbal prescriptions is a vital step in the prevention of future dispensing errors. You might consider, when appropriate, including the intended use on prescriptions for these products. Please inform your patients that they should carefully check all medications they receive, and immediately bring any problems, questions, or concerns to the pharmacist's attention.

If you become aware of a prescription dispensing error involving **KEPPRA**®, please contact UCB Pharma, Inc. immediately at 1-800-477-7877, option 9; the USP Medication Errors Reporting Program at 1-800-233-7767 or the FDA MEDWATCH program by telephone at 1-800-FDA-1088, by FAX at 1-800-FDA-0178, or by Internet <a href="http://www.fda.gov/medwatch">http://www.fda.gov/medwatch</a>.

Thank for your continued support in this very important matter.

Sincerely,

Leslie Magnus, MD Vice President, Medical Affairs UCB Pharma, Inc.